Pangaea Oncology S.A. Total Liabilities
Pangaea Oncology S.A. total liabilities. Based on the latest financial reports, Pangaea Oncology S.A. (PANG) has total liabilities worth €10.05 Million EUR (≈ $11.75 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Pangaea Oncology S.A. liquidity resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Pangaea Oncology S.A. (2013–2025)
Total liabilities of Pangaea Oncology S.A. from 2013 to 2025. This chart illustrates how Pangaea Oncology S.A.'s total liabilities have evolved over time, based on quarterly financial data.
Pangaea Oncology S.A. Competitors by Total Liabilities
The table below lists competitors of Pangaea Oncology S.A. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Naturel Yenilenebilir Enerji Ticare
IS:NATEN
|
Turkey | TL8.02 Billion |
|
ImmunoPrecise Antibodies Ltd.
NASDAQ:HYFT
|
USA | $8.40 Million |
|
DDC Enterprise Limited
NYSE MKT:DDC
|
USA | $843.97 Million |
|
Marketwise Inc
NASDAQ:MKTW
|
USA | $453.14 Million |
|
TsannKuen (China) Enterprise Co. Ltd
SHE:200512
|
China | HK$938.16 Million |
|
Dae Chang
KO:012800
|
Korea | ₩548.66 Billion |
|
Chilwa Minerals Ltd
AU:CHW
|
Australia | AU$1.60 Million |
|
Inzi Controls
KO:023800
|
Korea | ₩462.54 Billion |
Liability Composition Analysis (2013–2025)
This chart breaks down Pangaea Oncology S.A.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see balance sheet size of Pangaea Oncology S.A..
Liquidity & Leverage Metrics
Pangaea Oncology S.A. Total Liabilities Ratios Explained
Pangaea Oncology S.A. total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.78 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.47 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.31 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Pangaea Oncology S.A.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Pangaea Oncology S.A. (2013–2025)
The table below shows the annual total liabilities of Pangaea Oncology S.A. from 2013 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €10.05 Million ≈ $11.75 Million |
+5.02% |
| 2024-12-31 | €9.57 Million ≈ $11.19 Million |
-4.55% |
| 2023-12-31 | €10.03 Million ≈ $11.72 Million |
+89.10% |
| 2022-12-31 | €5.30 Million ≈ $6.20 Million |
-21.63% |
| 2021-12-31 | €6.76 Million ≈ $7.91 Million |
-21.40% |
| 2020-12-31 | €8.61 Million ≈ $10.06 Million |
+0.50% |
| 2019-12-31 | €8.56 Million ≈ $10.01 Million |
-27.04% |
| 2018-12-31 | €11.74 Million ≈ $13.72 Million |
-15.61% |
| 2017-12-31 | €13.91 Million ≈ $16.26 Million |
+16.96% |
| 2016-12-31 | €11.89 Million ≈ $13.90 Million |
+19.45% |
| 2015-12-31 | €9.95 Million ≈ $11.64 Million |
+45.67% |
| 2014-12-31 | €6.83 Million ≈ $7.99 Million |
+45.04% |
| 2013-12-31 | €4.71 Million ≈ $5.51 Million |
-- |
About Pangaea Oncology S.A.
Pangaea Oncology, S.A., a precision oncology company, provides a range of services to cancer patients in Spain and the rest of European Union countries. The company offers molecular diagnostics, including mutation analysis in tissue and liquid biopsy; gene amplification and translocation testing; immunohistochemistry (IHC) and fluorescence in-situ hybridization (FISH); gene expression profiling a… Read more